Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04617002
Expanded Access Status : Available
First Posted : November 5, 2020
Last Update Posted : November 4, 2021
Sponsor:
Information provided by (Responsible Party):
Chimerix

Brief Summary:
This is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical trials.

Condition or disease Intervention/treatment
Glioma H3 K27M Drug: ONC201

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Intermediate-size Population
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas



Intervention Details:
  • Drug: ONC201
    ONC201 is an oral, small molecule selective antagonist of DRD2

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  1. Patient meet one or more of the criteria below:

    Arm A

    1. Central nervous system tumor that is positive for the H3 K27M mutation (performed in a laboratory with CLIA or equivalent certification);
    2. Central nervous system tumor involving the thalamus, hypothalamus, basal ganglia, brainstem, cerebellum, cerebellar peduncle, midline cortex, corpus callosum, pineal region, optic tract, or optic chiasm.

      Arm B

    3. Diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons. H3 K27M status does not have to be known or positive for this arm.
  2. Arm A: Patient must have unequivocal radiographic evidence of progressive disease on as defined by RANO criteria or have documented recurrent glioma on diagnostic biopsy.

    Arm B: Patient are not required to have radiographic or clinical evidence of progressive disease.

  3. Arm A: Patient must be at least 90 days from completion of radiotherapy. Arm B: Patient must be at least 14 days from completion of radiotherapy.
  4. Patient must be at least 2 years of age.
  5. Patient must weigh at least 10kg.
  6. From the projected start of scheduled study treatment, the following time periods must have elapsed from prior anti-cancer treatments: 5 half-lives from any investigational agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from anti-cancer antibodies (except 21 days for bevacizumab), 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor therapies, and 1 week from devices used to treat cancer.
  7. Brain MRI within 21 days prior to start of study drug.
  8. Adequate organ and marrow function as defined below:

    1. Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to treatment (cycle 1 day 1, C1D1)
    2. Hemoglobin >8.0 mg/dL without red blood cell transfusion ≤ 3 days prior to C1D1
    3. Total serum bilirubin <1.5 X upper limit of normal (ULN)
    4. AST (SGOT)/ALT (SGPT) ≤2 X ULN; ≤ 5 X ULN if there is liver involvement secondary to tumor
    5. Serum creatinine ≤ 1.5 X ULN (OR creatinine clearance ≥ 60 mL/min/1.73 m2)
  9. For patients post pubertal: Female patients must agree to use effective contraception while taking ONC201 and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception while taking ONC201 and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator.
  10. Ability to understand a written informed consent document, and the willingness to sign it. Assent will be obtained when appropriate based on the subjects age.

Exclusion Criteria:

  1. Qualifies for participation in an ongoing ONC201 or ONC206 clinical trial.
  2. Previously or currently participating in an ONC201 clinical trial.
  3. Current or planned participation in a study of an investigational agent (including ONC206) or using an investigational device.
  4. Evidence of leptomeningeal disease or CSF dissemination of disease.
  5. Any known systemic infection that, in the opinion of the investigator, could compromise the safety of the patient, while taking ONC201.
  6. Prolongation of QT/QTcF interval (QTc interval >480 milliseconds) using Frederica's QT correction formula on two ECGs separated by at least 48 hours.
  7. A history of Torsades de Pointes or heart failure, hypokalemia, or family history of prolonged QT Syndrome
  8. Concomitant use of medication(s) known to prolong the QT/QTc interval

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04617002


Contacts
Layout table for location contacts
Contact: Rohinton Tarapore, PhD 1-919-806-1074 rtarapore@chimerix.com
Contact: Amy Felkins 1-919-806-1074 afelkins@chimerix.com

Locations
Layout table for location information
United States, California
Rady Children's Hospital Available
San Diego, California, United States, 92123
Contact: Megan Paul, MD       mrpaul@rchsd.org   
Providence Saint John's Health Center Available
Santa Monica, California, United States, 90404
Contact: Akanksha Sharma, MD       Akanksha.Sharma@providence.org   
United States, Colorado
Children's Hospital of Colorado Available
Aurora, Colorado, United States, 80045
Contact: Ashley Mettetal    720-777-5305    Ashley.Mettetal@childrenscolorado.org   
Principal Investigator: Kathleen Dorris, MD         
United States, District of Columbia
Children's National Medical Center Available
Washington, District of Columbia, United States, 20010
Contact: Lindsay Kilburn, MD, MS    202-476-3643    LKilburn@childrensnational.org   
United States, Florida
Miami Cancer Institute Available
Miami, Florida, United States, 33176
Contact: Yazmin Odia, MD, MS    786-596-2000    DG-MCIResearchNurses@baptisthealth.net   
Principal Investigator: Yazmin Odia, MD, MS         
United States, Georgia
ON HOLD: (currently not accepting new patients) Children's Healthcare of Atlanta, Emory University School of Medicine Available
Atlanta, Georgia, United States, 30322
Contact: Dolly Aguilera, MD    404-785-1112    AflacDevTReferral@choa.org   
United States, Hawaii
Kapi'olani Medical Center for Women and Children Available
Honolulu, Hawaii, United States, 96826
Contact: Andrea Siu, MPH    808-535-7169    Andrea.siu@hawaiipacifichealth.org   
Principal Investigator: Kelley Hutchins, DO         
United States, Iowa
University of Iowa Hospitals and Clinics Available
Iowa City, Iowa, United States, 52242
Contact: Mariko Sato, MD, PhD       mariko-sato@uiowa.edu   
United States, Michigan
University of Michigan Available
Ann Arbor, Michigan, United States, 48109
Contact: Misty Gravelin    734-763-0592    gravelim@med.umich.edu   
Principal Investigator: Carl Koschmann, MD, MS         
United States, Missouri
Washington University in St. Louis Available
Saint Louis, Missouri, United States, 63110
Contact: Andrew Cluster, MD       acluster@wustl.edu   
Contact: Alison Barnwell       abarnwell@wustl.edu   
Principal Investigator: Andrew Cluster, MD         
United States, New Jersey
Overlook Medical Center/ Atlantic Health System Available
Summit, New Jersey, United States, 07901
Contact: Jeanna Johnson    973-829-4869    Jeanna.Johnson@atlantichealth.org   
Principal Investigator: Robert Aiken, MD         
United States, New York
New York University Available
New York, New York, United States, 10016
Contact: Sharon Gardner, MD    646-929-7870    Sharon.Gardner@nyumc.org   
Contact: Anna Yaffe    212-263-9945    anna.yaffe@nyumc.org   
Principal Investigator: Sharon Gardner, MD         
University of Rochester Available
Rochester, New York, United States, 14627
Contact: David Korones, MD    585-275-2981    David_korones@urmc.rochester.edu   
Contact: Jennifer Serventi, PA    585-275-5863    Jennifer_serventi@urmc.rochester.edu   
United States, Texas
University of Texas Southwestern Available
Dallas, Texas, United States, 75390
Contact: Alison Patterson    214-456-2726    alison.patterson@childrens.com   
Principal Investigator: Daniel Bowers, MD         
United States, Virginia
Children's Hospital of The King's Daughters Available
Norfolk, Virginia, United States, 23507
Contact: Melissa Mark, MD       Melissa.Mark@CHKD.ORG   
Sponsors and Collaborators
Chimerix
Layout table for additonal information
Responsible Party: Chimerix
ClinicalTrials.gov Identifier: NCT04617002    
Other Study ID Numbers: ONC028
First Posted: November 5, 2020    Key Record Dates
Last Update Posted: November 4, 2021
Last Verified: March 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
TIC10 compound
Antineoplastic Agents